刘欢欢
中国医学科学院阜外医院 社区防治部
The effect of dietary sodium (salt) on cardiovascular disease (CVD) has been debated for a long time. The present study aims to explore whether salt intake affects the risk of cardiovascular disease in the Chinese population. Data from a prospective cohort study that included 954 men and women aged 35-59 years at baseline from four urban and rural population samples in China were used. Each participant collected their overnight urine for three consecutive days during two seasons to estimate sodium intake. CVD events, including incidences of coronary heart disease (CHD), stroke, and death from CVD, and all-cause mortality were tested by Cox proportional hazards models. After a median of 18.6 years of follow-up, CVD events occurred in 81 (8.5%) participants, including 20 CHD and 64 stroke events. All-cause deaths occurred in 149 (15.6%) participants, including 31 CVD-related deaths, 56 cancer-related deaths and 62 other-cause deaths. The hazard ratios and 95% confidence intervals for CVD events in each of the sodium excretion tertiles were 1.00, 1.66 (0.79-3.47) and 3.04 (1.46-6.34), P for trend = 0.001. This trend was also found for stroke incidence (P for trend < 0.001). The cardiovascular mortality risk increased as the sodium excretion levels rose after adjusting for confounding factors (P for trend = 0.043). However, this trend was not significant after adjusting for the baseline systolic blood pressure and antihypertensive medication use (P for trend = 0.171). No significant associations were found between sodium excretion and all-cause, cancer-related or other-cause mortality. High urinary sodium excretion was independently associated with an increased risk of cardiovascular disease in the general Chinese population.
Hypertension research : official journal of the Japanese Society of Hypertension 2018
OBJECTIVE:To evaluate the effects of metformin on systolic blood pressure (SBP) and diastolic blood pressure (DBP) in nondiabetic patients.METHODS:In this meta-analysis, we systematically searched PubMed, Embase, and the Cochrane Library through March 2016, and randomized controlled trials assessing the effects of metformin treatment compared with placebo were included. Random-effects models were used to estimate pooled mean differences in SBP and DBP.RESULTS:Twenty-eight studies from 26 articles consisting of 4113 participants were included. Pooled results showed that metformin had a significant effect on SBP (mean difference -1.98 mmHg; 95% confidence interval -3.61, -0.35; P = 0.02), but not on DBP (mean difference -0.67 mmHg; 95% confidence interval -1.74, 0.41; P = 0.22). In subgroup analysis, we found that the effect of metformin on SBP was significant in patients with impaired glucose tolerance or obesity (BMI ≥30 kg/m), with a mean reduction of 5.03 and 3.00 mmHg, respectively. Significant heterogeneity was found for both SBP (I = 60.0%) and DBP (I = 45.4%). A sensitivity analysis indicated that the pooled effects of metformin on SBP and DBP were robust to systematically dropping each trial. Furthermore, no evidence of significant publication bias from funnel plots or Egger's tests (P = 0.51 and 0.21 for SBP and DBP, respectively) was found.CONCLUSION:This meta-analysis suggested that metformin could effectively lower SBP in nondiabetic patients, especially in those with impaired glucose tolerance or obesity.
Journal of hypertension 2017
